Severe premenstrual syndrome may not be a single pattern of symptoms. Researchers at Uppsala University in Sweden have identified three distinct symptom timelines in premenstrual dysphoric disorder, or PMDD, according to ScienceAlert. The finding suggests the condition is currently diagnosed and treated as more uniform than it really is.
The work was published in Nature Communications. The authors say it could eventually support more personalized diagnosis and treatment, though the study is small and further research is needed.
PMDD is a severe form of premenstrual syndrome. ScienceAlert reported that the body is thought to react abnormally to the rise and fall of estrogen and progesterone. Symptoms can include anxiety, depression, irritability, fatigue, headaches, bloating, body aches and sleep problems. The condition is estimated to affect about 3 to 8 percent of people who menstruate regularly.
The Uppsala team followed 90 women with PMDD and 44 women without the disorder across two consecutive menstrual cycles. Participants reported their symptoms day by day. Computer models then sorted the data and revealed three subtypes among the women with PMDD.
The patterns differ in when symptoms start, how severe they become and how long they last:
The finding challenges the current diagnostic approach. A DSM-5 diagnosis relies on symptoms worsening in the week before menstruation and easing shortly after bleeding begins, but the new results suggest that is not how it unfolds for everyone.
The Swedish team is not the first to look at this. ScienceAlert reported that in 2019 an international group of researchers found three very similar trajectories among 74 people prospectively diagnosed with PMDD. That earlier study followed only one menstrual cycle.
The new study followed two cycles, and 98 percent of the participants with PMDD showed more than one symptom subtype during that time. In other words, a person's pattern is not necessarily fixed from one month to the next.
The authors acknowledge limits. The study is small, and ovulation was not measured directly. They argue the results support seeing PMDD as a complex, cyclical disorder tied to the interplay of hormones, brain and mental state.
ScienceAlert reported that PMDD is often dismissed as a normal part of the menstrual cycle, and that awareness of it is poor and misdiagnosis is common. In a 2026 editorial in the British Journal of General Practice, researchers wrote that current guidelines largely recommend similar management for PMDD and milder PMS. As a result, they said, patients with PMDD may be managed like those with milder PMS, which can lead to under-recognition of the impact on daily functioning, delayed escalation of treatment and a lack of follow-up.
The symptoms can seriously impair a person's ability to function and can include suicidal thoughts. A 2021 meta-analysis in the Journal of Women's Health found that PMDD was associated with nearly sevenfold higher odds of suicide attempts.
Treatment options are limited. Psychological support such as cognitive behavioral therapy may be recommended. Drug treatments such as oral contraceptive pills or selective serotonin reuptake inhibitors may also be advised. A significant share of patients do not respond to these therapies.
The researchers say more studies are needed to understand how PMDD symptoms appear and how they might be treated more effectively. ScienceAlert noted that recognizing different timelines could help explain why some patients respond to treatment and others do not. Treating every case as though it follows the same schedule, by contrast, may hide some of the biological mechanisms at work.
The authors said that combining dynamic symptom modeling with clinical practice could improve precision in mental health care for people who menstruate and reduce the burden of PMDD. The study does not yet change how the condition is diagnosed or treated.
Around Prague, based on reporting by ScienceAlert